These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1204 related items for PubMed ID: 15163773

  • 1. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
    Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA.
    N Engl J Med; 2004 May 27; 350(22):2239-46. PubMed ID: 15163773
    [Abstract] [Full Text] [Related]

  • 2. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A, Dworschack RT, Partin AW.
    J Urol; 2002 Aug 27; 168(2):504-8. PubMed ID: 12131298
    [Abstract] [Full Text] [Related]

  • 3. The influence of finasteride on the development of prostate cancer.
    Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA.
    N Engl J Med; 2003 Jul 17; 349(3):215-24. PubMed ID: 12824459
    [Abstract] [Full Text] [Related]

  • 4. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J, Haese A, Scattoni V, Steuber T, Chun FK, Briganti A, Montorsi F, Graefen M, Huland H, Karakiewicz PI.
    Cancer; 2008 Nov 15; 113(10):2695-703. PubMed ID: 18853417
    [Abstract] [Full Text] [Related]

  • 5. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
    Ahyai SA, Graefen M, Steuber T, Haese A, Schlomm T, Walz J, Köllermann J, Briganti A, Zacharias M, Friedrich MG, Karakiewicz PI, Montorsi F, Huland H, Chun FK.
    Eur Urol; 2008 Apr 15; 53(4):750-7. PubMed ID: 17964070
    [Abstract] [Full Text] [Related]

  • 6. Prevalence and clinical significance of prostate cancer among 12,682 men with normal digital rectal examination, low PSA levels (< or =4 ng/ml) and percent free PSA cutoff values of 15 and 20%.
    Pepe P, Panella P, Savoca F, Cacciola A, D'Arrigo L, Dibenedetto G, Pennisi M, Aragona F.
    Urol Int; 2007 Apr 15; 78(4):308-12. PubMed ID: 17495487
    [Abstract] [Full Text] [Related]

  • 7. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
    Freedland SJ, Mangold LA, Epstein JI, Partin AW.
    Urology; 2004 May 15; 63(5):887-91. PubMed ID: 15134972
    [Abstract] [Full Text] [Related]

  • 8. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK.
    Cancer; 2007 Apr 15; 109(8):1689-95. PubMed ID: 17330856
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttänen L, Auvinen A.
    J Urol; 2001 Oct 15; 166(4):1339-42. PubMed ID: 11547069
    [Abstract] [Full Text] [Related]

  • 11. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA.
    J Clin Oncol; 2007 Jul 20; 25(21):3076-81. PubMed ID: 17634486
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
    Etzioni RD, Howlader N, Shaw PA, Ankerst DP, Penson DF, Goodman PJ, Thompson IM.
    J Urol; 2005 Sep 20; 174(3):877-81. PubMed ID: 16093979
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen.
    Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM.
    N Engl J Med; 2003 Jul 24; 349(4):335-42. PubMed ID: 12878740
    [Abstract] [Full Text] [Related]

  • 17. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.
    D'Amico AV, Chen MH, Roehl KA, Catalona WJ.
    N Engl J Med; 2004 Jul 08; 351(2):125-35. PubMed ID: 15247353
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.